NCT05827796View on ClinicalTrials.gov

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Pancreatic Cancer
Interventions
DRUG

IN10018

IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.

DRUG

Albumin-Bound Paclitaxel

Albumin-bound paclitaxel will be administered as per the schedule specified in the respective arm.

DRUG

Gemcitabine

Gemcitabine will be administered as per the schedule specified in the respective arm.

DRUG

KN046

KN046 5 mg/kg on Day 1 of each 21-Day Cycle.

Trial Locations (1)

Unknown

RECRUITING

Renji Hospital of Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
lead

InxMed (Shanghai) Co., Ltd.

INDUSTRY